Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

GOVX
GeoVax Labs, Inc. New
stock NASDAQ

At Close
May 8, 2025 3:59:30 PM EDT
0.9573USD-1.309%(-0.0127)78,350
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 9, 2025 8:59:30 AM EDT
0.9799USD+1.021%(+0.0099)15,800
After-hours
May 8, 2025 4:49:30 PM EDT
0.9700USD+1.327%(+0.0127)2,875
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 21, 2022
05:21AM EST  GeoVax Labs 8-K Shows Co. Entered Securities Purchase Deal For Issuance, Sale To Purchaser Of 707.484K Shares, Pre-Funded Warrant To Purchase Up 2.36M Of Common Stock   Benzinga
Jan 20, 2022
09:00AM EST  GeoVax Announces Closing of $10 Million Private Placement   GlobeNewswire Inc
Jan 14, 2022
08:42AM EST  GeoVax Announces $10M Private Placement   Benzinga
08:41AM EST  GeoVax Announces $10 Million Private Placement   GlobeNewswire Inc
Jan 13, 2022
11:48AM EST  GeoVax Retains CATO SMS To Manage Gedeptin Phase 1/2 Clinical Trial   Benzinga
09:00AM EST  Activities Underway to Expand and Accelerate Enrollment of Ongoing Study for Head and Neck Cancer   GlobeNewswire Inc
Jan 11, 2022
09:00AM EST  via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced the appointment of Kelly T. McKee, Jr., M.D., M.P.H., to serve as the Companys Chief Medical Officer (CMO).   GlobeNewswire Inc
Jan 5, 2022
09:00AM EST  Conference Presentation to Include Updates onThree Ongoing Phase 2 Clinical Trials for COVID-19 and Cancer   GlobeNewswire Inc
Jan 4, 2022
09:11AM EST  GeoVax Chair, CEO Sends Letter To Shareholders   Benzinga
09:00AM EST  Letter from CEO Describes Achievements during 2021 and Sets Forth New Goals for 2022   GlobeNewswire Inc
Dec 15, 2021
09:03AM EST  GeoVax Announces Initiation Of Phase 2 Clinical Trial For COVID-19 Vaccine Booster   Benzinga
09:00AM EST  Ongoing Phase 1/2 Trial Advancing to Phase 2 Evaluation of Multi-Antigen Vaccine, Targeting both Spike and Nucleocapsid Proteins, as a Universal Booster to Current FDA-Approved Vaccines   GlobeNewswire Inc
Dec 14, 2021
09:04AM EST  GeoVax Receives Notice Of Allowance For Malaria Vaccine Patent From USPTO   Benzinga
09:00AM EST  The GeoVax Multi-antigenic MVA-VLP Approach Designedto Provide a Stronger, Broader Protection   GlobeNewswire Inc
Dec 6, 2021
10:40AM EST  GeoVax Receives Notice Of Allowance For U.S. Patent Titled 'Compositions and Methods for Generating an Immune Response to Treat or Prevent Malaria'   Benzinga
Dec 3, 2021
09:01AM EST  GeoVax Highlights Presentation Of Hemorrhagic Fever Vaccine Data At World Vaccine & Immunotherapy Congress   Benzinga
09:00AM EST  Nonhuman Primate Testing of Sudan and Marburg Vaccine Candidates Demonstrates Efficacious Immune Response   GlobeNewswire Inc
Dec 1, 2021
09:05AM EST  GeoVax Highlights Presentation Of COVID-19 Vaccine Data At World Vaccine & Immunotherapy Congress   Benzinga
09:00AM EST  GEO-CM02 Being Developed as a Universal Vaccine toAddress Evolving SARS-CoV-2 Variants such as Omicron   GlobeNewswire Inc
Nov 24, 2021
02:38PM EST  TD Ameritrade Tweets Says Geovax Chairman & CEO To Appear On The Watch List In Next Hour   Benzinga
Nov 17, 2021
09:06AM EST  GeoVax Highlights Presentation Of COVID-19 Vaccine Data At Vaccine World Asia Congress   Benzinga
09:00AM EST  GEO-CM02 Being Developed as a Universal Vaccine toAddress Evolving SARS-CoV-2 Variants   GlobeNewswire Inc
Nov 16, 2021
09:00AM EST  GeoVax Intellectual Property Portfolio Includes More than70 Granted/Pending Patent Applications   GlobeNewswire Inc
Nov 15, 2021
09:00AM EST  viaNewMediaWire --GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, announced today that it will be represented during presentations at the following upcoming scientific conferences.   GlobeNewswire Inc
Nov 11, 2021
04:02PM EST  Geovax Labs Q3 EPS $(0.31) Beats $(0.37) Estimate   Benzinga
04:00PM EST  Progress in Clinical Development of COVID-19 and Immuno-Oncology Programs   GlobeNewswire Inc
03:55AM EST  Earnings Scheduled For November 11, 2021   Benzinga
Nov 10, 2021
08:23AM EST  The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance   Benzinga
06:58AM EST  GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate   Benzinga
Nov 9, 2021
04:06PM EST  GeoVax, City of Hope Announce Agreement To Accelerate Development And Commercialization For City Of Hope's COVID-19 Vaccine   Benzinga
04:00PM EST  Phase 2 Vaccine Designed to Enhance Response for Immunocompromised Patients   GlobeNewswire Inc
Oct 18, 2021
09:00AM EDT  GeoVax Chief Scientific Officer to Participate in World Vaccine   GlobeNewswire Inc
Oct 14, 2021
09:07AM EDT  GeoVax Receives Notice Of Allowance For Ebola Vaccine Patent   Benzinga
09:00AM EDT  Single-dose of GEO-EM01 Provided 100% Protection inLethal Challenge Evaluation   GlobeNewswire Inc
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
07:27AM EDT  Shares of Georgia-headquartered GeoVax Labs, Inc. (GOVX) were rising more than 23 percent in pre-market trade after it announced an Assignment and License Agreement with PNP Therapeutics, Inc. that grants GeoVax exclusive rights to develop and commercialize Gedeptin, a novel patented product for the treatment of solid tumors.   RTTNews
07:07AM EDT  A Peek Into The Markets: US Stock Futures Gain Following Tuesday's Plunge   Benzinga
06:11AM EDT  The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 6.00 A.M. EDT).   RTTNews
Sep 28, 2021
04:01PM EDT  GeoVax Labs Reports Purchase Of Exclusive Rights To PNP Therapeutics' Development, Commercialization Of Gedeptin, No Terms Disclosed   Benzinga
04:00PM EDT  License ofGedeptinAdds Orphan Drug Clinical Program forTreatment of Advanced Head and Neck Cancers   GlobeNewswire Inc
Sep 7, 2021
09:00AM EDT  viaNewMediaWire --GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and cancer immunotherapies, announces today that Chairman & CEO David Dodd will present at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13-15, 2021.   GlobeNewswire Inc
Aug 20, 2021
02:42PM EDT  Mid-Afternoon Market Update: Crude Oil Down Over 2%; GeoVax Labs Shares Spike Higher   Benzinga
12:12PM EDT  Mid-Day Market Update: Nasdaq Rises 1%; HEXO Shares Plummet   Benzinga
10:15AM EDT  Mid-Morning Market Update: Markets Rise; Deere Beats Q3 Expectations   Benzinga
09:47AM EDT  Why Geovax Labs Shares Are Soaring Today   Benzinga
07:56AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Friday, Aug. 20, 2021: MUDS, BBIG, JD, BBY, GOVX   Benzinga
07:45AM EDT  The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data   Benzinga
06:03AM EDT  Pre-market Movers: GOVX, PROG, SONN, MRIN,   RTTNews
Aug 19, 2021
04:04PM EDT  GeoVax Highlights Presentation Of COVID-19 Vaccine Data At The European Society Of Medicine (ESMED) General Assembly   Benzinga
04:00PM EDT  GeoVax Vaccine Being Developed as a Universal Vaccine toAddress Evolving SARS-CoV-2 Variants   GlobeNewswire Inc
11:17AM EDT  GeoVax Labs Shares Spike On Volume, Co. Filed For New International Patent Application Titled 'VACCINES AND USES THEREOF TO INDUCE AN IMMUNE RESPONSE TO SARS-COV2'   Benzinga
Aug 12, 2021
09:04AM EDT  GeoVax to Present at the SNN Network Summer Virtual Event on   GlobeNewswire Inc
Aug 11, 2021
04:02PM EDT  Geovax Labs Q2 EPS $(0.21) Down From $(0.03) YoY   Benzinga
04:00PM EDT  GeoVax Reports 2021 Second Quarter Financial Results and Provides   GlobeNewswire Inc
09:06AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
04:27AM EDT  Earnings Scheduled For August 11, 2021   Benzinga
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 4, 2021
09:00AM EDT  Conference call to be held Wednesday, August 11, at 4:30 p.m. Eastern Time   GlobeNewswire Inc
Jul 22, 2021
09:01AM EDT  GeoVax Announces Presentation Of Sudan Ebolavirus Vaccine Data At American Society For Virology Annual Meeting   Benzinga
09:00AM EDT  GeoVax Announces Presentation of Sudan Ebolavirus Vaccine Data at   GlobeNewswire Inc
Jul 7, 2021
09:01AM EDT  GeoVax Highlights Yesterday Report Co Issued Hepatitis B Vaccine Patent   Benzinga
09:00AM EDT  Vaccine Would Address Therapeutic Medical Need of Over 250 Million Worldwide   GlobeNewswire Inc
Jul 6, 2021
12:02PM EDT  Geovax Labs Granted U.S. Patent Titled 'Compositions and methods for generating an immune response to hepatitis B virus'   Benzinga
Jun 10, 2021
11:00AM EDT  via NewMediaWire--GeoVax Labs, Inc.(Nasdaq: GOVX), a biotechnology company developing human immunotherapies and vaccines against infectious diseases and cancers, announced today that it will be participating in the Alliance Global Partners Virtual Healthcare Symposium being held on Thursday, June 17, 2021.   GlobeNewswire Inc
Jun 7, 2021
09:00AM EDT  GeoVax Chairman & CEO to Participate in Vaccine Panel Discussion   GlobeNewswire Inc
May 13, 2021
05:13PM EDT  Small-Cap Biotech Execs On Latest Advancements, Post-Pandemic Return To Fundamentals   Benzinga
10:07AM EDT  From BZ Global Small Cap Conference: GeoVax Labs CEO David A. Dodd Says Current Focus Is Universal Coronavirus Program   Benzinga
10:01AM EDT  From BZ Global Small Cap Conference: GeoVax Labs CEO David A. Dodd Says COVID-19 Vaccine Animal Testing Data To Come In H1'21   Benzinga
May 6, 2021
04:00PM EDT  Additional Capital Raised to Support Acceleration ofCoronavirus and Immuno-Oncology Programs   GlobeNewswire Inc
11:30AM EDT  GeoVax Chairman & CEO David Dodd to Participate in Panel Discussion   GlobeNewswire Inc
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
Apr 26, 2021
09:00AM EDT  GeoVax to Report First Quarter 2021 Financial Results on Thursday,   GlobeNewswire Inc
Apr 16, 2021
11:17AM EDT  GeoVax Granted U.S. Patent Titled 'Multivalent HIV Vaccine Boost Compositions and Methods of Use'   Benzinga
Apr 9, 2021
10:45AM EDT  Shares of GeoVax Labs, Inc. (GOVX) are rising more than 25% Friday morning at $5.59.   RTTNews
Apr 1, 2021
09:37AM EDT  Therapeutic Vaccine Would Address Medical Need of Over 250 Million Worldwide   GlobeNewswire Inc
09:37AM EDT  GeoVax Labs Reports US Patent For Co.'s 'Composition and Methods of Generating an Immune Response to Hepatitis B Virus'   Benzinga
Mar 26, 2021
04:39PM EDT  Highlights From Day 2 Of Benzinga's Biotech Small Cap Conference   Benzinga
Mar 23, 2021
04:31PM EDT  GeoVax Labs Reports FY20 Sales $1.823M Up From $1.176M YoY   Benzinga
04:30PM EDT  GeoVax Reports 2020 Year-End Financial Results And Provides   GlobeNewswire Inc
04:26AM EDT  Earnings Scheduled For March 23, 2021   Benzinga
Mar 17, 2021
09:00AM EDT  GeoVax Chairman & CEO David Dodd to Present Corporate OverviewGeoVax CSO, Mark Newman, PhD, to Participate in Immuno-Oncology Panel Discussion   GlobeNewswire Inc
Mar 15, 2021
09:00AM EDT  Conference call to be held Wednesday, March 24, at 8:00 a.m. Eastern Time   GlobeNewswire Inc
Mar 10, 2021
09:00AM EST  GeoVax to Participate in Maxim Groups Inaugural   GlobeNewswire Inc
Mar 4, 2021
09:58AM EST  GeoVax Announces Filing Of Two Additional COVID-Related Patent Applications   Benzinga
09:55AM EST  Filings Made in Corporate Focus Areas of SARS-CoV-2 and Immuno-Oncology   GlobeNewswire Inc
Mar 3, 2021
09:00AM EST  GeoVax to Present at the H.C. Wainwright Global Life Sciences   GlobeNewswire Inc
Mar 1, 2021
09:00AM EST  Meet with GeoVax CEO David Dodd & CFO Mark Reynolds who will Deliver a Presentation Titled Advancing a Unique Broad-based Vaccine Approach to Fighting COVID-19, Ebola & Beyond   GlobeNewswire Inc
Feb 15, 2021
10:44AM EST  A Look Into Healthcare Sector Value Stocks   Benzinga
Feb 11, 2021
02:00PM EST  GeoVax Announces Closing of $10.3 Million Bought Deal Offering   GlobeNewswire Inc
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 8, 2021
11:43PM EST  GeoVax Announces Pricing of $9.0 Million Bought Deal Offering   GlobeNewswire Inc
Feb 1, 2021
09:47AM EST  5 Value Stocks In The Healthcare Sector   Benzinga
Jan 11, 2021
02:33PM EST  Mid-Afternoon Market Update: Dow Falls 100 Points; GeoVax Labs Shares Spike Higher   Benzinga
12:32PM EST  Mid-Day Market Update: Silver Rises Over 2%; Applied DNA Sciences Shares Plunge   Benzinga
10:16AM EST  Mid-Morning Market Update: Markets Open Lower; AZZ Earnings Top Views   Benzinga
09:01AM EST  GeoVax Awarded NIH Grant to Advance COVID-19 Vaccine Development   Benzinga
09:00AM EST  Company Focused on Single-dose Vaccine Against Multiple COVID Strains   GlobeNewswire Inc
Jan 5, 2021
09:00AM EST  GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual   GlobeNewswire Inc
Dec 10, 2020
10:12AM EST  Mid-Morning Market Update: Markets Mixed; Adobe Earnings Top Views   Benzinga
Dec 7, 2020
12:46PM EST  Maxim Group Analyst, Jason McCarthy, Comments On GeoVax, Tells Benzinga There Is No Particular News Today But Says Positive News Around COVID-19 Vaccine Space May Be Impacting Stock   Benzinga
Nov 30, 2020
10:34AM EST  GeoVax Labs Inc. (GOVX, GOVXW) said that it has signed a Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases or NIAID, part of the National Institutes of Health or NIH, in support of GeoVax's non-clinical development of vaccines against numerous pathogens. Financial terms of the License Agreement were not disclosed.   RTTNews
10:20AM EST  A Look Into Healthcare Sector Value Stocks   Benzinga
09:02AM EST  UPDATE: GeoVax Says License Agreement 'provides GeoVax with access to certain materials and patent rights owned by agencies of the Department of Health and Human Services' For Creation Of Ebola, Zika And Malaria, Among Others   Benzinga
09:01AM EST  GeoVax Announces License Agreement With NIH To 'Support Continued Advancements in Vaccine Development'   Benzinga
09:00AM EST  GeoVax Announces License Agreement With NIH to Support Continued   GlobeNewswire Inc
Nov 19, 2020
11:29AM EST  Maxim Group Initiates Coverage On Geovax Labs with Buy Rating, Announces Price Target of $8   Benzinga
Nov 5, 2020
06:10PM EST  Geovax Labs Earlier Reported Q3 EPS $(0.73), Sales $415.00K Beat $333.00K Estimate   Benzinga
05:37PM EST  Geovax Labs Q3 EPS $(0.73), Sales $415.00K Beat $333.00K Estimate   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Oct 30, 2020
10:08AM EDT  Conference call to be held Friday, November 6, at 8:15 a.m. Eastern Time   GlobeNewswire Inc
Oct 28, 2020
09:00AM EDT  GeoVax CEO David Dodd to Participate in Virtual Webinar Hosted by   GlobeNewswire Inc
Oct 26, 2020
09:05AM EDT  GeoVax Shares Spike Higher, Up 31%; Co Announces License Agreement With NIH To Support Coronavirus Vaccine Development   Benzinga
09:00AM EDT  GeoVax Announces License Agreement with NIH to Support COVID-19   GlobeNewswire Inc
Oct 12, 2020
03:30PM EDT  Q3 The Busiest Since 2014 For IPOs, Led By Unicorns, SPACs   Benzinga
Sep 29, 2020
02:00PM EDT  GeoVax Announces Closing of $12.8 Million Public Offering and   GlobeNewswire Inc
Sep 25, 2020
05:39AM EDT  GeoVax Priced 2.56M Unit Public Offering @$5/Unit; Announced Uplisting to Nasdaq and 1:20 Reverse Stock Split   Benzinga
Sep 24, 2020
09:23PM EDT  GeoVax Announces Pricing of $12.8 Million Public Offering;   GlobeNewswire Inc
Sep 15, 2020
09:00AM EDT  GeoVax to Participate in World Vaccine Congress Session Addressing   GlobeNewswire Inc
Sep 3, 2020
09:42AM EDT  GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of   GlobeNewswire Inc
Aug 26, 2020
09:00AM EDT  GeoVax Appoints Mark J. Newman, Ph.D. Chief Scientific Officer   GlobeNewswire Inc
Aug 24, 2020
09:00AM EDT  GeoVax Announces Clinical Trial Initiation of Novel Combination   GlobeNewswire Inc
Aug 13, 2020
09:00AM EDT  via NEWMEDIAWIRE -- GeoVax Labs, Inc., a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today a multi-party collaboration for the development of Sudan ebolavirus (SUDV) and Marburg virus (MARV) vaccine candidates. SUDV and MARV cause viral hemorrhagic fevers.   GlobeNewswire Inc
Aug 10, 2020
09:00AM EDT  Company Demonstrated Progress on COVID-19 Vaccine Development;Continued Progress in Other Infectious Disease and Immuno-Oncology Programs   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC